<DOC>
	<DOCNO>NCT00394485</DOCNO>
	<brief_summary>Study compare efficacy safety tiotropium + beta agonist ( procaterol ) vs. tiotropium alone among patient moderate chronic obstructive pulmonary disease</brief_summary>
	<brief_title>Tiotropium + Procaterol v Tiotropium + Placebo COPD Patients</brief_title>
	<detailed_description>This study aim determine efficacy safety tiotropium plus procaterol comparison tiotropium plus placebo Filipino patient see Manila , moderate COPD . After 1-week wash-out period , 6-minute walk test , St. George 's Respiratory Questionnaire ( SGRQ ) administer prior run-in period 1 week wherein patient start tiotropium alone . The patient randomly allocate either two arm two-week treatment , follow one week washout , crossed-over treatment another two week . The procaterol placebo dose give 2 hrs tiotropium dose .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Procaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . GOLD criterion moderate COPD ( postbronchodilator ) FEV1/FVC &lt; 70 % 50 % â‰¤ FEV1 &lt; 80 % predict With without symptom 2 . Willing undergo treatment protocol sign informed consent 1 . Exacerbation within 1 month prior runin period 2 . Significant hypoxemia and/or desaturation rest exercise . 3 . Significant cardiac , renal , systemic disease 4 . History adverse reaction two test drug ( tiotropium procaterol )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Procaterol</keyword>
	<keyword>Tiotropium</keyword>
</DOC>